PULSE the living trend engine
🤖 Open Intelligence Dossier available for AI agents & citation View Markdown (.md) →
◼ Archived Business

McKesson, CD&R near $5 billion-plus deal to buy Option Care, FT reports

Option Care Health stock skyrocketed following a $5.8 billion buyout agreement with McKesson and CD&R.

12sources
14articles
12velocity
+385%since first seen
42d agofirst detected

Velocity

How fast coverage is spreading — measured hourly from article rate × source diversity. How this works →

The brief

Recent reporting outlines a major corporate transaction involving the acquisition of Option Care Health. According to coverage from Bloomberg.com, Reuters, Axios, WSJ, Yahoo Finance, Investor's Business Daily, KSL News, Quiver Quantitative, TradingView, Demócrata, The Motley Fool, and The Business Journals, McKesson and CD&R are joining forces to buy Option Care Health. The deal values the infusion therapy provider at approximately $5.8 billion, or $32.05 per share. Outlets note that the agreement will take the company private. Stock market reactions were immediate, with coverage from The Motley Fool and Quiver Quantitative highlighting that Option Care Health stock skyrocketed on Tuesday following the announcement. Financial publications and news agencies have extensively covered the transaction details.

Reporting from Reuters initially noted that the parties were near a five billion-plus deal before subsequent updates confirmed the $5.8 billion valuation. Demócrata reported the purchase value in different currency terms reflecting European coverage, while TradingView and Investor's Business Daily emphasized McKesson's specific role in taking a stake and striking the multibillion-dollar transaction. The Business Journals also briefly mentioned a separate transaction involving Energy Transfer buying Vaquero for $2.6 billion alongside the broader business news cycle. Context surrounding the acquisition centers on Option Care Health's position as an at-home infusion therapy provider, a detail underscored by WSJ, Reuters, and KSL News. Taking the company private through the combined efforts of CD&R and McKesson marks a significant consolidation within the healthcare and infusion services sector. The available coverage extensively documents the per-share pricing and the total financial scope of the buyout without detailing prior acquisition discussions or historical corporate friction.

Future updates from the cited financial news networks will track the formal closing process of the private buyout. Coverage does not yet specify the exact calendar date when the transaction will officially finalize. Stakeholders will also monitor regulatory reviews and shareholder filings as reported by the outlets tracking the developments. As the corporate transition proceeds, market analysts continue to evaluate the implications for the healthcare sector. Readers should consult ongoing reports from Reuters, Bloomberg.com, and Yahoo Finance for official corporate communications regarding the timeline.

Synthesized by PULSE from the headlines below under a strict no-invention contract. ✓ fact-checked: all claims supported by sources Updated 40d ago.

Quick answers

Who is acquiring Option Care Health?

McKesson and CD&R are acquiring Option Care Health.

What is the valuation of the deal?

The deal is valued at approximately $5.8 billion, with shares priced at $32.05.

What type of business does Option Care Health operate?

Option Care Health operates as an infusion therapy provider.

Coverage (14)

Topics

Related trends

\n \n \n \n \n \n \n